Burkitt Lymphoma · line 1 · Hyper-CVAD + Rituximab (CD20+) — alternating courses A/B, 8 cycles total
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-HYPER-CVAD-R |
| ID | IND-BURKITT-1L-HYPERCVAD-R |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-BURKITT |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 1L alternative to R-CODOX-M/IVAC for fit younger high-risk Burkitt. Center experience often dictates choice between these two intensive protocols. Older / unfit / lower-risk → DA-EPOCH-R.
Used By
No reverse references found in the YAML corpus.